Making the Case for Novel SERDs

EMBER-3 trial data may lead to a new FDA approval while muddying waters for second-line endocrine therapy in ER-positive, HER2-negative advanced breast cancer.

New data showing benefit from adding a CDK4/6 inhibitor to endocrine therapy and anti-HER2 therapy in triple-positive advanced breast cancer change practice.

Data show two paclitaxel regimens had similar outcomes in high-risk, HR-positive, HER2-negative early breast cancer, raising questions about optimal selection.

A phase 3 clinical trial found that neoadjuvant camrelizumab plus chemo improves the rate of pathological complete response in early or locally advanced TNBC.

Key studies in HR-positive, HER2-negative early breast cancer at SABCS 2024 inform practice and “springboard to some additional questions,” says Erin Frances Cobain, MD.

The ZEST trial was designed to guide treatment in breast cancer based on MRD, but was ended when it didn’t accrue enough patients. Results may still offer insights.

An exploratory biomarker analysis suggests that tumor mutational burden and T-cell–inflamed gene expression may relate to treatment response in early-stage TNBC.

Data from the COMET clinical trial support the safety and efficacy of active monitoring in HR-positive, HER2-negative, low-risk ductal carcinoma in situ.

Trastuzumab deruxtecan outperforms chemo in HR+, HER2-low/ultralow metastatic breast cancer with rapid progression after endocrine therapy, new data show.

Phase 2 data show that the investigational HER2-directed ADC SHR-A1811 was effective and well-tolerated in patients with HER2-positive breast cancer.

Despite growing evidence supporting PRO monitoring in patients with breast cancer, institutions have been slow to adopt the practice, said experts at SABCS 2024.

Imlunestrant may offer significant protection against disease progression for patients with ESR1-mutated ER-positive, HER2-negative advanced breast cancer.